Kristin Brooks04.28.21
Rentschler Biopharma and Vetter, two global CDMOs, have advanced their strategic collaboration, establishing a framework for their alliance and set up a governance structure, as well as implemented guidelines for their joint approach across functions. Along with starting their first joint client projects, they are also working closely on existing projects and related topics.
The collaboration initiated in mid-2020, aims to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster. The companies are mutually enhancing their services by offering complementary skills and experience along the biopharmaceutical value chain.
The established framework consists of an overall collaboration agreement that regulates the intended contributions of both parties to ultimately generate added value for clients. Further operational agreements and guidelines between various departments including Quality, Development Service and Logistics have been implemented. These cover key standards for joint approaches as well as core inputs and processes across both organizations to align interfaces and optimize services for the client’s convenience and long-term planning.
The alignment of departments also includes the companies’ global business development teams. The companies have also defined the target markets for their collaboration, focusing on Europe, U.S. and the Asia-Pacific, as well as emerging markets.
“The formation of the mutual agreements and alignment on a client approach were foundational steps that both Vetter and Rentschler Biopharma identified early in our exploration of this strategic alliance,” said Vetter Managing Director Peter Soelkner. “We look forward to the new progress that this step will facilitate.”
“We are very interested to see how the experience gained in these initial projects will further enhance our strategic alliance,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “These client engagements will provide valuable insights for our teams to leverage in refining the alignment of our processes and approaches.”
The collaboration initiated in mid-2020, aims to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster. The companies are mutually enhancing their services by offering complementary skills and experience along the biopharmaceutical value chain.
The established framework consists of an overall collaboration agreement that regulates the intended contributions of both parties to ultimately generate added value for clients. Further operational agreements and guidelines between various departments including Quality, Development Service and Logistics have been implemented. These cover key standards for joint approaches as well as core inputs and processes across both organizations to align interfaces and optimize services for the client’s convenience and long-term planning.
The alignment of departments also includes the companies’ global business development teams. The companies have also defined the target markets for their collaboration, focusing on Europe, U.S. and the Asia-Pacific, as well as emerging markets.
“The formation of the mutual agreements and alignment on a client approach were foundational steps that both Vetter and Rentschler Biopharma identified early in our exploration of this strategic alliance,” said Vetter Managing Director Peter Soelkner. “We look forward to the new progress that this step will facilitate.”
“We are very interested to see how the experience gained in these initial projects will further enhance our strategic alliance,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “These client engagements will provide valuable insights for our teams to leverage in refining the alignment of our processes and approaches.”
